Results 111 to 120 of about 8,387 (243)
Journal of Clinical MedicineObjective: The present systematic review assessed the efficacy of peri-procedurally administered trimetazidine in the prevention of contrast-induced nephropathy (CIN) in patients undergoing coronary interventions with contrast agents.
Tiny Nair +3 more
semanticscholar +1 more source
The effect of trimetazidine on left ventricular function and hospitalisation in ischaemic heart failure patients in Hospital Universiti Sains Malaysia [PDF]
, 2021 Background : Trimetazidine is primarily used in persistent angina in ischaemic heart disease patients. A few studies showed the potential benefit of trimetazidine in heart failure patients.
Mojolou, Roberta Angelo
core
MODERN PECULIARITIES OF MYOCARDIAL CYTOPROTECTION IN THERAPY OF ISHEMIC HEART DISEASE PATIENTS
Медицинский совет, 2016 Results of meta-analysis of more than 20 clinical studies of use of various dosages and schemes of indication of trimetazidine to stable ischemic heart disease patients allowed considering the daily dosage of trimetazidine 70 mg as a standard therapeutic
Z. M. SIZOVA, S .K. VLADIMIROV
doaj +1 more source
Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
Кардиоваскулярная терапия и профилактика, 2005 Metabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine.
L. V. Kremneva +2 more
doaj
Trimetazidine – a metabolic modulator in performance sports [PDF]
Background: Trimetazidine, used in the treatment of angina pectoris, is a metabolic modulator that optimizes cellular myocardial energy metabolism in hypoxia.
Cocman, Valeria, Timercan, Tatiana
core
Gomal Journal of Medical Sciences, 2010 Background: Ischemic heart disease is the leading cause of heart failure. This study was conducted to see the effect of Trimetazidine on left ventricular function in heart failure secondary to ischemic heart disease.
Shimal Khan +4 more
doaj
Prevention of Heart Failure in Rats by Trimetazidine Treatment: A Consequence of Accelerated Phospholipid Turnover? [PDF]
, 2020 Heart failure is known for alteration of cardiac catecholamine responsiveness involving adrenergic receptor (AR) down-regulation. Trimetazidine, a metabolically active anti-ischemic drug, accelerates the turnover of phospholipids.
A B +8 more
core
IntroductionPulmonary fibrosis (PF) and tissue remodeling can greatly impair pulmonary function and often lead to fatal outcomes.MethodologyIn the present study, we explored a novel molecular interplay of long noncoding (Lnc) RNA CBR3-AS1/ miRNA-29 ...
Elhawary, Nasser Attia +13 more
core +1 more source
Appreciation of trimetazidine treatment in experimental sepsis rat model
, 2015 Introduction: Our aim was to determine the efficacy of trimetazidine on experimental sepsis rat ...
Inal, V +5 more
core +1 more source
HOLTER ECG MONITORING AND TREATMENT EFFECTIVENESS CONTROL IN PATIENTS AFTER MYOCARDIAL INFARCTION
Российский кардиологический журнал, 2010 In total, 316 patients after Q wave myocardial infarction (Q-MI) were randomised into 3 groups. For 6 months after discharge, the control group (n=103) received standard therapy (aspirin, enalapril, metoprolol, simvastatin). Group 1 (n=107) also received
U. A. Islamova +4 more
doaj